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Summary.-One hundred and ninety-one adults with acute myelogenous leukaemia
were treated with combination chemotherapy consisting of daunorubicin and
cytosine arabinoside (Barts III). Sixty-three patients achieved remission and were
admitted to one of3 trials of active immunotherapy: immunotherapy alone, immuno-
therapy and maintenance chemotherapy or neither of these. All patients had weekly
clinical and blood examination and monthly marrow examination. Reinduction
chemotherapy was given as soon as relapse was diagnosed in the marrow. The
most striking observation was that immunotherapy was associated with easy and
repeated reinduction of remission and marked prolongation of survival after first
relapse when compared with immunotherapy plus chemotherapy. The possible
reasons for this and the value of immunotherapy are discussed in relation to thethird
trial still in progress which includes 2 maintenance arms, immunotherapy alone and
surveillance only.
IN 1971 we began a trial of active
immunotherapy for acute myelogenous
leukaemia (AML) using a regime of
remission induction and maintenance
which was based upon that of Crowther
et al. (1973) but included routine monthly
diagnostic marrow examination for the
early detection of relapse. We found that
second remissions were the rule (6/7
patients), while third and subsequent
remissions commonly occurred (Freeman
et al., 1973), in contrast to the general
experience that relativelv few patients
achieved second remission in adult AML
(Wiernik and Serpick, 1970; Bailey et al.,
1971; Crowther et al., 1973; Powles, 1973;
Powles et al., 1973, 1977). There are few
reports of third remissions (Whittaker
and Slater, 1977), although we have
achieved at least 750 third remissions in
some groups of patients. Following the
encouraging results from our first trial, we
subsequently participated in randomized
MRC trials of immunotherapy which
necessitated several changes of thera-
peutic protocol; nevertheless the use of
monthlv marrow examination remained
constant.
The present communication describes
our experience over a 6-year period of 3
trials of active immunotherapy in AML
in which immunotherapy has been asso-
ciated with relatively short first remis-
sions but easy second and subsequent
remission with long post-relapse survival
and an excellent quality of life.
PATIENTS AND METHODS
Patients entered into 3 Manchester AML
trials since 1971 and followed up to 15 March
1977, have received one of the therapeutic
protocols summarized in Table I. Patients
were not selected, and all who were referred
to Manchester Royal Infirmary were treated.
The diagnosis of AML was confirmed by
blood examination and by marrow examina-
tion carried out by sternal or iliac-crest
puncture. The aspirated material was fixed,ACTIVE IMMUNOTHERAPY IN AML
stained and examined usually on the same
day. Complete remission was judged to have
occurred when the aspirate showed <5 /0
blasts with no abnormal forms, recovery of
other normal elements, a rising peripheral
platelet and neutrophil count, a steady or
rising haemoglobin level not maintained by
transfusion, and the absence of abnormal
clinical signs. All patients who went into
remission were seen weekly for clinical assess-
ment and for blood counts. Marrow exami-
nation was at monthly intervals, and relapse
wNas diagnosed on the basis of an increased
level of abnormal blasts (>5%/). If the blast
count showed a slight rise, say 5-8%, marrow
examination was repeated within 2 weeks.
A blast count >80 was taken as definite
indication of relapse, even in the absence of
clinical and peripheral blood changes. Immu-
notherapy with irradiated allogeneic AML
blast cells and BCG (Glaxo) was admini-
stered at weekly intervals as described
previously (Freeman et al., 1973).
RESULTS
One hundred and ninety-one patients
have been entered into the Manchester
AML trials since October 1971, and 63
have achieved remission, an overall in-
duction rate of 33%/'. Fig. 1 is a life table
of survival from presentation for patients
who remitted, using the 5 protocols
summarized in Table I. Table II sum-
marizes the data relevant to length of
first remission, frequency of second and
subsequent remissions and duration of
survival after first relapse. Seven patients
are still in their first remission and 10
patients have survived more than 2 years
from first relapse. Of the 9 surviving long-
est, 2 have survived for 5 years, 2 over 4
years and the rest have survived over
3 years. The survival curves in Fig. 1 do
not show any statistical difference be-
tween the different arms of treatment.
Amongst the 39 patients who achieved
first remission but who have since died,
the average duration of survival following
first relapse was > 8 months. Although
there was no significant difference in
overall survival after relapse, including
living patients in the second trial, the
average times between first relapse and
death was 290-7 days for patients receiving
immunotherapy only and 145-6 for those
receiving immunotherapy with mainte-
nance chemotherapy (Fig. 2). This differ-
ence is highly significant (P<0-01) al-
though this method of analysis may be
open to criticism (R. Peto, personal
communication).
DISCUSSION
Our first remission-induction figures are
lower than the best reported (e.g. Gale
TABLE I.-Manchester Immunotherapy Trial Protocols
Phase
Induction
*N + 1
Consolidation
Maintenance chemotherapy
Immunotherapy
Trial I
(Pilot)
A
+
B
Trial II Trial III
(MRC VI) (MRC VI modified)
A
Nil
Nil Randomize
Nil or C
I I
A
±
B
Nil
Randomize
I or Nil
* N + 1 = one extra course of (launorubicin and cytosine arabiiioside once marrow
indicated remission.
A=Daunorubicin 1-5 mg/'kg on Day 1.
Cytosine arabinoside (Ara C) 2-0 mg/kg daily by i.v. pulse Barts III induction
Days 1-5 f
B=Cyclophosphamide 200 mg/M2 weekly for 6 weeks.
Thioguanine 2-5 mg/kg daily for 6 weeks.
C = 5-daycourse of Arc C+ThioguanineandAalternatingmonthly,exceptthatdosage
of thioguanine was 2-0 mg/kg (laily orally (Barts chemotherapy maintenance).
I= 109 irradiated allogeneic leukaemic cells plus 106 Glaxo BCG (Freeman et al.,
1973).
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FIG. 1.-Life table showing survival from presentation of 63 patients who remitted using the 5 proto-
cols summarised in Table I (Manchester immunotherapy trials I, II and III). * Q I imm. n = 7;
*-A II imm. + chem. n = 9; * D II imm. n = 20; v-V III imm. n = 16; * > III nil
n = 11.
and Kline, 1977) but are not unusually
low for the Barts III regime (Powles et al.,
1973, 1977) and could be improved if
better facilities for supportive care were
available. However, it is important to
take the induction rate into consideration
when analysing reinduction frequency,
since a low first-remission induction rate
may conceivably eliminate relatively drug-
resistant patients before randomization.
Adequate induction chemotherapy prob-
ably plays a large part in determining
length of first remission and duration of
survival. For example, patients in the
first Manchester immunotherapy trial
had significantly better first-remission
lengths and duration of survival than the
immunotherapy-only arm of the second
trial. The difference in survival is signifi-
cant only at 2 years (P<005, Table I) and
is attributed to the omission of cyto-
reduction (consolidation) chemotherapy
from the MRC 6th AML trial protocol.
Maintenance chemotherapy may in this
case have partly compensated for in-
adequate induction treatment. Those
patients who achieved remission have
generally experienced remarkably good
overall survival times, even following
relapse. First-remission length is not
correlated with duration of survival in our
series, mainly because second and subse-
quent remissions have been achieved in a
high proportion of patients, and second
and subsequent remissions were often
longer than the first. It is likely that
routine monthly marrow examination
while in remission is partly responsible
for both short remissions and easy re-
induction. This practice allows early
diagnosis of relapse and prompt re-
introduction of chemotherapy whilst the
leukaemia cell mass is still small. If
marrow examination is not carried out
i
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FIG. 2. Life table showing survival after relapse
in Manchester II Trial. 0 immunotherapy n
P<0.01.
routinely or carried out only when the
peripheral-blood examination or clinical
signs suggest that relapse is imminent,
first remission length may appear to be
relatively long, but reinduction in the
presence of more advanced relapse may be
more difficult and consequently post-
relapse survival short.
Immunotherapy appears to prolong
first remission (Crowther et al., 1973;
Powles et al., 1977), facilitate reinduction
(Freeman et al., 1973) and lengthen post-
relapse survival (Powles et al., 1977).
These observations have received some
support in the results of the MRC VI
trial (1978). It is still not clear whether
immunotherapy is actively beneficial or
whether the apparent advantages are due
to avoidance of drug resistance and to
monthly marrow examination.
Our current direct trial is designed to
400
on (days)
500 600 700
for patients who died (excluding long survivors)
17; * immunotherapy + chemotherapy it = 5.
overcome these uncertainties by comparing
immunotherapy with no treatment during
remission (Table I). This trial allows for
the first time an assessment of immuno-
therapy uncomplicated by maintenance
chemotherapy. The patients in both arms
of the trial are subject to identical weekly
clinical and haematological assessment
and routine monthly marrow examination.
Although it is still too early to analyse
this third Manchester trial in terms of
length of survival, it is interesting to
note that the median duration of first
remission is 30 weeks for the 16 immuno-
therapy patients and only 22 weeks for 11
patients in the surveillance-only group.
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APPENDIX
Datafor 63 Patients Randomized into Manchester First, Second and Third Trials
(to April 1977).
First Survival
remission after Survival from
Trial Manchester length relapse presentation
No. Diagnosis trial Treatment (days) (days) (days)
M/C1 AML I Imm. 161 757 984
M/C6 AMML I Imm. 196 56 311
M/C14 AML I Imm. 126 341 499
M/Cl9 AML I Imm. 602 1137 1771 Alive
M/C21 AMML I Imm. 98 1608 1757 Alive
M/C26 EL I Imrn. 126 952 1089
M/C29 AML I Imm. 1438 180 1644 Alive
M3 AML II Imm. 140 333 560
M7 AML II Imm. 77 1346 1460 Alive
M18 AMML II Imm. 21 198 262
M23 AMML II Imm. 126 332 536
M30 AML II Imm. 628 1259 1314 Alive
M33 AMML II Imm. 84 249 404
M34 AML II Imm. 49 78 201
M37 EL and AML II Imm. 168 226 457
M40 AML II Imm. 245 353 668
M45 AML I I Imm. 535 388 492
M48 AML II Imm. 35 936 1096 Alive
M52 AML II Imm. 42 66 163
M56 AML II Imm. 70 226 396
M60 EL and AML II Imm. 84 286 536
M65 AML II Imm. 77 306 786
M66 AMML II Imm. 273 690 1060
M75 AML II Imm. 91 158 330
M77 AMML II Inm. 77 281 442
M79 AMML II Imm. 119 315 473
M87 AML II Imm. 112 457 642R. HARRIS ET AL.
First
remission
Manchester length
trial Treatment (days)
I. and C.
I. and C.
I. and C.
I. and C.
I. and C.
I. and C.
I. and C.
I. and C.
I. and C.
Imm.
lmm.
Imm.
Imm.
Imm.
Imm.
Imm.
Imm.
Imm.
Imm.
Imm.
Imm.
Imm.
Imm.
Imm.
Imm.
147
252
126
56
63
259
63
70
441
107
81
645
457
109
246
130
359
441
203
238
99
210
219
140
68
No maintenance 87
No maintenance 165
No maintenance 89
No maintenance 522
No maintenance 98
No maintenance 173
No maintenance 328
No maintenance 78
No maintenance 154
No maintenance 126
No maintenance 175
Survival
after
relapse
(days)
161
1160
155
1182
86
859
260
66
281
39
201
In remission
243
162
198
35
186
In remission
84
14
150
In remission
40
In remission
In remission
84
441
95
In remission
36
147
In remission
130
122
35
5
Diagnosis
AML
AML
AML
AMML
AML
AMML
AMML
AML
AML
AML
EL
AMOL
APL
AMML
AML
AML
AML
AMML
AML
APL
AML
EL
AML
AML
AML
Trial
No.
M9
M14
M15
M32
M44
M47
M51
M71
M91
M83
M84
MiOl
M106
M107
MI18
M125
M131
M127
M136
M150
M152
M156
M153
M158
M160
M88
M90
M108
M128
M129
M141
M145
M147
M151
M157
M155
II
Ir
II
II
II
II
II
II
II
III
III
III
III
III
III
III
III
III
III
III
III
III
III
III
III
III
III
III
III
III
III
III
III
III
III
III
Survival from
presentation
(clays)
378
1412 Alive
317
1305 Alive
248
1201 Alive
404
280
860 Alive
268
368
795 Alive
748 Alive[
330
499
278
545 Alive
572 Alive
362
326 Alive
313
229 Alive
283 Alive
147 Alive
105 Alive
260
784
224
563 Alive
148
383
390 Alive
262
318 Alive
203 Alive
244 Alive
AMML
AML
AML
EL
AML
AMML
AMML
AML
EL
AML
AML
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